Innovent Biologics, Inc. (HKG:1801)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
82.05
-7.05 (-7.91%)
Oct 22, 2026, 2:05 PM HKT

Innovent Biologics Stock Forecast

Stock Price Forecast

According to 30 analysts polled by S&P Global, Innovent Biologics stock has a consensus rating of "Strong Buy" and an average price target of $129.74. The average 1-year stock price forecast is 58.12% higher than the current stock price, while the lowest is $94.69 (+15.41%) and the highest is $156.71 (+90.99%).

Price Target: $129.74 (+58.12%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$94.69$129.74$128.17$156.71
Change+15.41%+58.12%+56.21%+90.99%

Analyst Ratings

The average analyst rating for Innovent Biologics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingMay '26Jun '26Jul '26Aug '26Sep '26Oct '26
Strong Buy222221202121
Buy666777
Hold211222
Sell000000
Strong Sell000000
Total302928293030

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Unknown Analyst
UBS
No rating
UBS
Buy
Maintains
$135.30
BuyMaintains$135.30+64.90%Oct 19, 2026
CMB International Securities
CMB International Securities
Buy
Maintains
$130.25 → $138.63
BuyMaintains$130.25 → $138.63+68.96%Oct 16, 2026
Unknown Analyst
Bernstein
No rating
Bernstein
Buy
Maintains
$128.00
BuyMaintains$128.00+56.00%Sep 22, 2026
Unknown Analyst
Citic Securities
No rating
Citic Securities
Buy
Maintains
$125.00
BuyMaintains$125.00+52.35%Sep 17, 2026
DBS
DBS
Buy
Reiterates
$144.00
BuyReiterates$144.00+75.50%Sep 14, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
18.61B
from 13.04B
Increased by 42.67%
Revenue Next Year
23.07B
from 18.61B
Increased by 23.97%
EPS This Year
1.42
from 0.99
Increased by 43.08%
EPS Next Year
2.16
from 1.42
Increased by 52.42%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
4.27B4.56B6.21B9.42B13.04B18.61B
Revenue Growth
11.08%6.71%36.21%51.82%38.42%42.67%
Gross Profit
3.05B3.17B4.40B7.16B10.00B16.04B
Gross Margin
71.32%69.67%70.89%76.03%76.66%86.18%
Operating Income
-2.70B-3.12B-1.56B-123.30M733.62M2.57B
Net Income
-2.73B-2.18B-1.03B-94.63M813.57M2.32B
EPS
----0.991.42
EPS Growth
-----43.08%
Forward PE
----42.6749.30
Free Cash Flow
----9.73B2.71B
No. Analysts
-----28
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.

Revenue Forecast

Revenue202620272028
High19.8B
Avg18.6B
Low17.2B

Revenue Growth

Revenue Growth202620272028
High
51.8%
Avg
42.7%
Low
31.5%

EPS Forecast

EPS202620272028
High2.11
Avg1.42
Low1.06

EPS Growth

EPS Growth202620272028
High
113.2%
Avg
43.1%
Low
7.1%